Safety and Effectiveness of BOTOX® for Lateral Canthal Lines With or Without Simultaneous Glabellar Lines in Korea

Allergan

Status: Completed

Conditions: Lateral Canthal Lines; Crow's Feet Lines

Treatments: Biological: Botulinum Toxin Type A

Study type: Observational

Funder types: Industry

Identifiers

NCT02248844

191622-147

Details and patient eligibility

About

This is a postmarketing surveillance study in Korea to evaluate the safety and effectiveness of BOTOX® for lateral canthal lines (crow's feet lines) with or without simultaneous glabellar lines.

Enrollment: 667 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subject and Investigator decision to treat crow's feet lines with Botox®

Exclusion criteria

• None

Trial design

667 participants in 1 patient group

Botulinum Toxin Type A

Description:

Subjects who receive botulinum toxin Type A injected into crow's feet line areas per clinical practice.

Treatment:

Biological: Botulinum Toxin Type A